Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hepatic nuclear corepressor 1 regulates cholesterol absorption through a TRβ1-governed pathway
Inna Astapova, … , David E. Cohen, Anthony N. Hollenberg
Inna Astapova, … , David E. Cohen, Anthony N. Hollenberg
Published April 8, 2014
Citation Information: J Clin Invest. 2014;124(5):1976-1986. https://doi.org/10.1172/JCI73419.
View: Text | PDF
Research Article Hepatology

Hepatic nuclear corepressor 1 regulates cholesterol absorption through a TRβ1-governed pathway

  • Text
  • PDF
Abstract

Transcriptional coregulators are important components of nuclear receptor (NR) signaling machinery and provide additional mechanisms for modulation of NR activity. Expression of a mutated nuclear corepressor 1 (NCoR1) that lacks 2 NR interacting domains (NCoRΔID) in the liver leads to elevated expression of genes regulated by thyroid hormone receptor (TR) and liver X receptor (LXR), both of which control hepatic cholesterol metabolism. Here, we demonstrate that expression of NCoRΔID in mouse liver improves dietary cholesterol tolerance in an LXRα-independent manner. NCoRΔID-associated cholesterol tolerance was primarily due to diminished intestinal cholesterol absorption as the result of changes in the composition and hydrophobicity of the bile salt pool. Alterations of the bile salt pool were mediated by increased expression of genes encoding the bile acid metabolism enzymes CYP27A1 and CYP3A11 as well as canalicular bile salt pump ABCB11. We have determined that these genes are regulated by thyroid hormone and that TRβ1 is recruited to their regulatory regions. Together, these data indicate that interactions between NCoR1 and TR control a specific pathway involved in regulation of cholesterol metabolism and clearance.

Authors

Inna Astapova, Preeti Ramadoss, Ricardo H. Costa-e-Sousa, Felix Ye, Kaila A. Holtz, Yingxia Li, Michele W. Niepel, David E. Cohen, Anthony N. Hollenberg

×

Figure 2

Effects of hepatic expression of NCoRΔID on plasma lipoprotein and whole-body cholesterol content.

Options: View larger image (or click on image) Download as PowerPoint
Effects of hepatic expression of NCoRΔID on plasma lipoprotein and whole...
(A) Cholesterol concentrations were measured in FPLC fractions of pooled plasma from animals with indicated genotypes fed a 2% cholesterol diet for 3 weeks (n = 6–9 animals per group). (B) VLDL clearance was blocked in control and L-ΔID mice on Lxra+/+ and Lxra–/– backgrounds by intravenous injection of 600 mg/kg tyloxapol. VLDL accumulation in blood was assessed by measuring plasma triglycerides at indicated time points. Animals were kept on high-cholesterol diet for 3 weeks prior to the experiment (n = 5–8 animals per group). (C) Whole carcasses (excluding liver and gut) of mice with indicated genotypes fed 2% cholesterol for 3 weeks were digested in ethanolic KOH, and whole-body cholesterol content was measured (n = 5–8 animals per group). (D) Expression of Ldlr, Mylip (Idol), and Scarb1 was measured by QPCR in the livers of animals after 3 days of 2% cholesterol feeding (n = 6–8 animals per group). Statistical analysis was performed using 2-way ANOVA with Bonferroni’s post-tests. *P ≤ 0.05; **P ≤ 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts